Ang Lifesciences India Limited

BSE: 540694
Ang Lifesciences India Limited - pharma in Amritsar, Punjab, India. FY 2026 financials & compliance.
CIN L24230PB2006PLC030341 Incorporated 14 June 2006 ROC Chandigarh HQ Amritsar, Punjab, India
Active Listed - BSE: 540694 Public Limited Company pharma MSME · Medium
Data last updated
Market Cap
₹44.59 Cr
ANG · BSE
Share Price
₹33.00
-3.37% today
Revenue
₹92.89 Cr
FY 2025-26 · +0.0% YoY
EBITDA
₹0.70 Cr
Margin 0.8%
Net Profit
−₹11.09 Cr
FY 2025-26 · +7.3% YoY
Authorised capital
₹14 Cr
Registered with MCA
Paid-up capital
₹13.06 Cr
Issued & subscribed
Open charges
₹81.62 Cr
Satisfied ₹13.33 Cr

About Ang Lifesciences India Limited

Data last updated:

Ang Lifesciences India Limited is a public limited company based in Amritsar, Punjab, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 14 June 2006 and has been in existence for over 20 years.

The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN L24230PB2006PLC030341. Its GSTIN is 03AAHCA5390H1ZS (Punjab). The company holds 4 GST registrations, of which 3 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 540694.

The company has an authorised share capital of ₹14 Cr and a paid-up capital of ₹13.06 Cr. It was formerly known as Ang Lifesciences Private Limited. It is led by directors including Rajesh Gupta (Managing Director) and Saruchi Gupta (Whole-Time Director).

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Amritsar, Punjab.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹92.89 Cr, a growth of 0% compared to the previous year. For the same year it recorded a net loss of ₹11.09 Cr (net margin -11.9%) and EBITDA of ₹70 Lakh (EBITDA margin 0.8%). The net worth stands at ₹52.89 Cr (down 17.3% YoY). Total assets are valued at ₹133.7 Cr (down 10% YoY).

The company has about 459 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: ANG Lifesciences. As per MCA filings, the company has open charges of ₹81.62 Cr and satisfied charges of ₹13.33 Cr on record. Court records list 122 cases involving the company, including 31 filed by the company and 91 filed against it; 57 cases are pending. The company has 34 deals on record (33 market trades, 1 ipo); the latest was in January 2024. Its 8 peer companies in the Pharma industry (Formulations, Lifesciences), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is XL Laboratories Private Limited with revenue of ₹96.06 Cr.

Ang Lifesciences India Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-PB-01-0001714). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website anglifesciences.com.

Company details

CIN L24230PB2006PLC030341
Registration Number 030341
Incorporation Date 14 June 2006
ROC Chandigarh
Listing Status Listed - Listed on BSE (540694)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-PB-01-0001714

Name history

Ang Lifesciences India has undergone 3 name changes throughout its history. The company was previously known as Ang Lifesciences Private Limited, Ang Lifesciences India Limited, and Ang Lifesciences India Private Limited. The current legal name is Ang Lifesciences India Limited.

Company NameStatus
Ang Lifesciences India LimitedCurrent
Ang Lifesciences Private LimitedPrevious
Ang Lifesciences India LimitedPrevious
Ang Lifesciences India Private LimitedPrevious

CIN history

Ang Lifesciences India has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230PB2006PLC030341, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24230PB2006PLC030341Current
U24230PB2006PTC030341Previous
U24230PB2006PLC030341Previous
Key People
Rajesh Gupta Managing Director Saruchi Gupta Whole-Time Director Sukhpal Singh Director

Recognitions & Rankings of Ang Lifesciences India

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-PB-01-0001714

Contact details

Ang Lifesciences India Limited's registered office is in Amritsar, Punjab. Its website is anglifesciences.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    anglifesciences.com
  • Registered Address
    Darbara Complex SCO 113 First Floor District Shopping Centre B Block Ranjit, Avenue, Amritsar, Punjab, India – 143001
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Ang Lifesciences India Limited, buy the company report.

Comprehensive company report
Ang Lifesciences India Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Ang Lifesciences India operates one associated brand: ANG Lifesciences. Each brand links to its own profile.

BrandDescriptionWebsite
ANG Lifesciences
Dry Powder Injectables are contract manufactured and exported.anglifesciences.com

Business activity

The main business activity of Ang Lifesciences India is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Ang Lifesciences India Limited, buy the company report.

Financials of Ang Lifesciences India Limited

FY 2025-26 filings available

Ang Lifesciences India Limited reported revenue of ₹92.89 Cr (up 0% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹92.89 Cr
+0.0% YoY
EBITDA
₹0.70 Cr
+136.6% YoY
Profit After Tax
−₹11.09 Cr
+7.3% YoY
Net Worth
₹52.89 Cr
-17.3% YoY
Total Assets
₹134 Cr
-10.0% YoY
Total Debt
₹79.40 Cr
-4.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Income statement
Revenue92.8992.85146220354
Revenue growth+0.0%-36.5%-33.6%-37.9%-
EBITDA0.70(1.91)8.3714.7467.90
EBITDA margin+0.8%-2.1%+5.7%+6.7%+19.2%
Profit before tax(13.02)(15.70)(10.71)2.6353.50
Net profit(11.09)(11.96)(8.58)(0.18)40.39
Net profit margin-11.9%-12.9%-5.9%-0.1%+11.4%
EPS (₹)(8.43)(9.51)(7.77)(0.20)38.89
Balance sheet
Total assets134149153164179
Net worth52.8963.9876.2886.2283.77
Total debt79.4083.2172.8470.7577.00
Cash & bank3.793.645.746.186.65
Net working capital74.1184.3984.8770.8281.88
Cash flow
Cash from operations11.03(0.26)(9.49)26.3824.72
Cash from investing1.05(1.59)19.89(9.33)(44.41)
Cash from financing(11.74)1.68(10.40)(17.07)19.93
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue15.3023.5018.7326.0524.6016.8224.7332.88
Revenue growth (YoY)-37.8%+39.7%-24.3%-20.8%+33.6%---
Other income0.110.170.160.120.090.65(0.27)0.35
EBITDA(1.95)2.67(2.69)0.080.64(0.70)(2.15)2.28
EBITDA margin-12.7%+11.4%-14.4%+0.3%+2.6%-4.2%-8.7%+6.9%
Depreciation1.501.771.511.521.531.421.961.74
Interest2.242.181.931.891.942.422.002.18
Profit before tax(5.58)(1.11)(5.97)(3.21)(2.74)(3.89)(6.38)(1.29)
Tax(1.34)0.28(1.21)(0.27)(0.73)(1.83)(1.19)0.80
Net profit(4.24)(1.39)(4.76)(2.94)(2.01)(2.06)(5.19)(2.09)
EPS (₹)(3.24)(1.07)(3.60)(2.24)(1.52)(1.56)(3.98)(1.53)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue91.6089.91131207349154127
Revenue growth+1.9%-31.6%-36.5%-40.6%+126.0%+21.6%-
EBITDA6.61(1.47)7.8311.6765.5515.3412.43
EBITDA margin+7.2%-1.6%+6.0%+5.6%+18.8%+9.9%+9.8%
Profit before tax(5.19)(12.94)(8.85)2.0753.079.878.40
Net profit(4.73)(9.90)(7.07)(0.39)39.717.266.09
Net profit margin-5.2%-11.0%-5.4%-0.2%+11.4%+4.7%+4.8%
EPS (₹)(3.52)(7.92)(6.62)(0.51)38.3113.9911.76
Balance sheet
Total assets13013914014816386.8658.45
Net worth62.2266.8177.0785.5483.4841.3534.55
Total debt66.8470.5859.3655.5660.9942.4020.83
Cash & bank3.583.555.506.056.590.113.60
Net working capital77.6380.8082.0965.0376.6456.5037.35
Cash flow
Cash from operations13.72(2.29)(13.13)26.0127.39(11.18)4.83
Cash from investing(3.33)(1.63)20.02(9.35)(42.50)(7.79)(1.66)
Cash from financing(10.19)3.92(7.00)(16.75)15.2918.81(3.95)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue13.9622.8018.3025.9724.5317.6723.9132.16
Revenue growth (YoY)-43.1%+29.0%-23.5%-19.3%+51.6%---
Other income0.190.190.160.210.170.75(0.03)0.36
Total expenses15.4218.1820.3823.7522.6818.0325.8929.70
EBITDA(1.46)4.62(2.08)2.221.85(0.36)(1.98)2.46
EBITDA margin-10.5%+20.3%-11.4%+8.5%+7.5%-2.0%-8.3%+7.6%
Depreciation1.471.731.451.451.451.301.841.62
Interest1.771.651.611.591.612.051.711.87
Profit before tax(4.51)1.43(4.98)(0.61)(1.04)(2.96)(5.56)(0.67)
Tax(1.09)0.33(0.74)0.18(0.24)(1.02)(1.00)0.41

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue15.3023.5018.7326.0524.6016.8224.7332.88
Revenue growth (YoY)-37.8%+39.7%-24.3%-20.8%+33.6%---
Other income0.110.170.160.120.090.65(0.27)0.35
EBITDA(1.95)2.67(2.69)0.080.64(0.70)(2.15)2.28
EBITDA margin-12.7%+11.4%-14.4%+0.3%+2.6%-4.2%-8.7%+6.9%
Depreciation1.501.771.511.521.531.421.961.74
Interest2.242.181.931.891.942.422.002.18
Profit before tax(5.58)(1.11)(5.97)(3.21)(2.74)(3.89)(6.38)(1.29)
Tax(1.34)0.28(1.21)(0.27)(0.73)(1.83)(1.19)0.80
Net profit(4.24)(1.39)(4.76)(2.94)(2.01)(2.06)(5.19)(2.09)
EPS (₹)(3.24)(1.07)(3.60)(2.24)(1.52)(1.56)(3.98)(1.53)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Revenue92.8992.85146220354
Revenue growth+0.0%-36.5%-33.6%-37.9%-
Other income0.542.020.709.720.90
Total expenses92.1994.76138205286
Employee cost0.0017.4519.3523.9721.29
EBITDA0.70(1.91)8.3714.7467.90
EBITDA margin+0.8%-2.1%+5.7%+6.7%+19.2%
Depreciation6.336.768.379.355.88
Interest7.939.0511.4112.489.42
Profit before tax(13.02)(15.70)(10.71)2.6353.50
Tax(1.93)(3.29)(0.57)2.8913.19
Net profit(11.09)(11.96)(8.58)(0.18)40.39
Net profit margin-11.9%-12.9%-5.9%-0.1%+11.4%
EPS (₹)(8.43)(9.51)(7.77)(0.20)38.89
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Equity & liabilities
Share capital13.0613.0613.0613.0610.37
Reserves & surplus35.1446.2358.5368.4768.71
Shareholders' funds (net worth)52.8963.9876.2886.2283.77
Minority interest0.000.000.000.000.00
Secured loans69.4364.3763.2462.2867.38
Unsecured loans9.9718.849.608.479.62
Total debt79.4083.2172.8470.7577.00
Total liabilities134149153164179
Assets
Gross block125126121147142
Net block50.6157.1958.4088.1592.61
Capital work in progress0.000.000.000.000.00
Investments0.030.030.030.030.03
Inventories47.7654.1147.7748.4936.96
Sundry debtors67.9366.5473.2883.15102
Cash & bank balances3.793.645.746.186.65
Loans & advances31.3841.0646.5345.3347.15
Total current assets151165173183193
Total current liabilities76.7580.9688.45112111
Net working capital74.1184.3984.8770.8281.88
Total assets134149153164179
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Opening cash0.160.320.320.350.11
Net cash from operating activities11.03(0.26)(9.49)26.3824.72
Net cash from investing activities1.05(1.59)19.89(9.33)(44.41)
Net cash from financing activities(11.74)1.68(10.40)(17.07)19.93
Net change in cash0.34(0.16)(0.01)(0.02)0.23
Closing cash3.793.645.746.186.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Growth
Sales growth+0.0%-36.5%-33.6%-37.9%-
EBITDA growth+136.7%-122.8%-43.2%-78.3%-
PBT growth+17.1%-46.6%--95.1%+9997.0%
Net income growth+7.3%-39.4%-4666.7%-100.5%-
Revenue CAGR (3Y)-25.0%-36.0%---
EBITDA CAGR (3Y)-63.8%----
Profitability & leverage
Net income margin-11.9%-13.4%-6.9%-0.1%+11.4%
Return on capital employed--4.4%+1.4%+8.3%+35.1%
Return on net worth--17.7%-10.6%-0.2%+48.1%
Debt / equity-1.110.880.870.92
Long-term debt / equity-0.270.230.250.26
Interest cover-140.85-104.38-231.5415.19
Efficiency & per share
Fixed asset turnover-0.751.091.522.50
Inventory turnover-1.823.045.159.59
Debtors turnover-1.331.872.373.47
EPS (₹)(8.43)(9.51)(7.77)(0.20)38.89
Dividend per share (₹)0.000.000.000.001.00
Book value per share (₹)0.0045.4054.8262.4376.28
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue13.9622.8018.3025.9724.5317.6723.9132.16
Revenue growth (YoY)-43.1%+29.0%-23.5%-19.3%+51.6%---
Other income0.190.190.160.210.170.75(0.03)0.36
Total expenses15.4218.1820.3823.7522.6818.0325.8929.70
EBITDA(1.46)4.62(2.08)2.221.85(0.36)(1.98)2.46
EBITDA margin-10.5%+20.3%-11.4%+8.5%+7.5%-2.0%-8.3%+7.6%
Depreciation1.471.731.451.451.451.301.841.62
Interest1.771.651.611.591.612.051.711.87
Profit before tax(4.51)1.43(4.98)(0.61)(1.04)(2.96)(5.56)(0.67)
Tax(1.09)0.33(0.74)0.18(0.24)(1.02)(1.00)0.41
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue91.6089.91131207349154127
Revenue growth+1.9%-31.6%-36.5%-40.6%+126.0%+21.6%-
Other income0.732.440.849.840.950.750.42
Total expenses84.9991.38124195283139114
Employee cost0.0014.4515.9020.2718.3214.357.10
EBITDA6.61(1.47)7.8311.6765.5515.3412.43
EBITDA margin+7.2%-1.6%+6.0%+5.6%+18.8%+9.9%+9.8%
Depreciation6.086.277.758.525.122.241.23
Interest6.457.649.7710.928.313.983.22
Profit before tax(5.19)(12.94)(8.85)2.0753.079.878.40
Tax(0.46)(2.59)(0.22)2.7313.362.612.31
Net profit(4.73)(9.90)(7.07)(0.39)39.717.266.09
Net profit margin-5.2%-11.0%-5.4%-0.2%+11.4%+4.7%+4.8%
EPS (₹)(3.52)(7.92)(6.62)(0.51)38.3113.9911.76
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.0613.0613.0613.0610.375.185.18
Reserves & surplus48.8053.3963.6567.7968.4234.7229.37
Shareholders' funds (net worth)62.2266.8177.0785.5483.4841.3534.55
Secured loans52.0153.8951.2148.7852.7538.0818.03
Unsecured loans14.8316.698.156.788.244.322.80
Total debt66.8470.5859.3655.5660.9942.4020.83
Total liabilities13013914014816386.8658.45
Assets
Gross block91.3290.9585.3910810337.5733.73
Net block47.0652.6353.3478.6882.3221.8920.94
Capital work in progress0.000.000.000.000.000.400.23
Investments3.523.523.523.523.520.020.02
Inventories33.0037.8434.2437.3929.1719.2610.00
Sundry debtors65.3564.9669.2778.1198.9958.7846.06
Cash & bank balances3.583.555.506.056.590.113.60
Loans & advances35.2844.4549.3646.6546.8233.7413.00
Total current assets13715115816818211272.66
Total current liabilities59.5870.0076.2810310555.3935.31
Net working capital77.6380.8082.0965.0376.6456.5037.35
Total assets13013914014816386.8658.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.080.090.200.290.110.274.37
Net cash from operating activities13.72(2.29)(13.13)26.0127.39(11.18)4.83
Net cash from investing activities(3.33)(1.63)20.02(9.35)(42.50)(7.79)(1.66)
Net cash from financing activities(10.19)3.92(7.00)(16.75)15.2918.81(3.95)
Net change in cash0.20(0.01)(0.12)(0.08)0.17(0.16)(0.77)
Closing cash3.583.555.506.056.590.113.60
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.9%-31.6%-36.5%-40.6%+126.0%+21.6%-
EBITDA growth+549.7%-118.8%-32.9%-82.2%+327.3%+23.4%-
PBT growth+59.9%-46.2%--96.1%+437.7%+17.5%+3.5%
Net income growth+52.2%-40.0%-1712.8%-101.0%+447.0%+19.2%-
Revenue CAGR (3Y)-23.8%-36.4%-5.2%+17.7%+42.0%+26.6%+23.3%
EBITDA CAGR (3Y)-17.3%--20.1%-2.1%+77.9%+28.0%+24.1%
Profitability & leverage
Net income margin-5.2%-11.5%-6.6%-0.3%+11.4%+4.7%+4.8%
Return on capital employed--3.8%+1.7%+7.8%+49.1%+19.1%+20.7%
Return on net worth--14.4%-8.7%-0.5%+63.6%+19.1%+19.3%
Debt / equity-0.900.710.690.830.830.67
Long-term debt / equity-0.170.140.140.140.150.18
Interest cover1,216.98-98.7112,212.50346.6713.7530.3828.75
Efficiency & per share
Fixed asset turnover-1.021.361.964.964.333.85
Inventory turnover-2.493.676.2214.4010.5515.34
Debtors turnover-1.341.782.344.422.942.89
EPS (₹)(3.52)(7.92)(6.62)(0.51)38.3113.9911.76
Dividend per share (₹)0.000.000.000.001.000.000.00
Book value per share (₹)0.0050.8858.7461.9176.0076.9966.67

To see the full year-wise statements and ratios of Ang Lifesciences India Limited, buy the company report.

Board of directors of Ang Lifesciences India Limited

Ang Lifesciences India has 6 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sukhpal Singh
Also directs: Dorfie Ventures LLP, Famyl Hospitality Private Limited
Director02 May 201610 Years 5 MonthsCurrent
Chetna
Also directs: Akg Exim Limited, Plaza Wires Limited, Ems Limited and 5 more
Director12 Oct 20215 Years 0 MonthsCurrent
Rajesh Gupta
Also directs: Mansa Print and Publishers Limited, Ang Healthcare India Private Limited, Baddi Agro Private Limited and 4 more
Managing Director14 Jun 200620 Years 4 MonthsCurrent
Saruchi Gupta
Also directs: Mansa Print and Publishers Limited, Baddi Agro Private Limited, Jammu Distillers Private Limited and 3 more
Whole-Time Director01 Apr 201115 Years 6 MonthsCurrent
Harvinder Singh Dhami
Also directs: Amanaya Ventures Limited
Director27 May 20242 Years 4 MonthsCurrent
Rohit Mittal
Also directs: Mansa Print and Publishers Limited
Director11 Oct 20233 Years 0 MonthsCurrent
View all directors

Peer comparison

Ang Lifesciences India Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations, Lifesciences), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
XL Laboratories Private Limited₹96.06 Cr (FY 2025)17.0%New Delhi, Delhi, India
Yeluri Formulations Private Limited₹96.05 Cr (FY 2025)-23.0%Hyderabad, Telangana, India
MCW Healthcare Private Limited₹95.35 Cr (FY 2024)16.0%Madhya Pradesh, India
Surmount Laboratories Limited₹95.33 Cr (FY 2024)-6.0%Mumbai, Maharashtra, India
Bio-Med Private Limited₹94.67 Cr (FY 2025)19.0%Uttar Pradesh, India
Impulse Pharma Private Limited₹94.61 Cr (FY 2024)12.0%Thane, Maharashtra, India
Chiron Behring Vaccines Private Limited₹94.53 Cr (FY 2025)30.0%Bhor, Maharashtra, India
Cosmas Research Lab Limited₹93.42 Cr (FY 2025)60.0%Ludhiana, Punjab, India
Ang Lifesciences India Limitedthis company₹92.89 Cr (FY 2026)-₹11.09 Cr-11.9%0.0%459Amritsar, Punjab, India

To see the full peer comparison of Ang Lifesciences India Limited, buy the company report.

Auditor

Ang Lifesciences India Limited is audited by Singh Bhupinder & Associates for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Singh Bhupinder & AssociatesFY 2024035417N

Shareholding

Shareholding for the quarter ended Mar 2026: promoters hold 70.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 29.40%.

Promoters: 70.60%Retail & Others: 29.40%
Mar 2026
QUARTER
70.60% Promoters
29.40% Retail & Others
Promoter holding - history
Now 70.60% · Mar 2026High 70.60% · Jun 2025Low 70.60% · Jun 2025
69%69.8%70.5%71.3%72%Jun 2025Sep 2025Dec 2025Mar 2026Jun 2025: 70.60%Sep 2025: 70.60%Dec 2025: 70.60%Mar 2026: 70.60%70.60%70.60%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025
Promoters70.60%70.60%70.60%70.60%
Public29.40%29.40%29.40%29.40%

Charges & borrowings

Open charges
₹81.62 Cr
Satisfied charges
₹13.33 Cr
Breakdown by lending institutions
Others₹63.80 Cr
Canara Bank₹10.00 Cr
Hdfc Bank Limited₹6.16 Cr
Axis Bank Limited₹1.00 Cr
Punjab National Bank₹0.66 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
05 Mar 2024100889924Others₹5 CrOpen
19 Oct 2022100627777Others₹5 CrOpen
31 Mar 2022100561689Others₹18 LakhOpen
07 Jan 2022100567386Others₹1.2 CrOpen
06 Jan 2022100533305Canara Bank₹10 CrOpen

To see the full charge records of Ang Lifesciences India Limited, buy the company report.

Total charge records: 28 View all charges

Deals & funding

Ang Lifesciences India Limited has 34 deals on record (33 market trades, 1 ipo); the latest was in January 2024.

Total deals
34
Market trades
33
IPO
1

Deals on record (5 of 34)

WhenDealAmountParties
Nov 2021Market trade₹7.14 CrBuyer: Alpha Leon Enterprises LLP
Seller: Alpha Leon Enterprises LLP
Sep 2021Market trade₹1.12 CrSeller: Ways Vinimay Pvt Ltd
Aug 2021Market trade₹1.13 CrSeller: Ways Vinimay Pvt Ltd
Aug 2021Market trade₹1.7 CrSeller: Ways Vinimay Pvt Ltd
Sep 2020Market trade₹13.4 LakhSeller: Display Commercial Private Limited

To see the full deal history of Ang Lifesciences India Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Ang Lifesciences India Limited was last rated by Icra on 28 Oct 2021.

Rating agencyRated onRating
Icra28 Oct 2021

To see the full credit ratings and regulatory alerts of Ang Lifesciences India Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Ang Lifesciences India Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Group structure & subsidiaries

Ang Lifesciences India has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Mansa Print and Publishers LimitedU22110PB2003PLC054383

To see the full group structure of Ang Lifesciences India Limited, buy the company report.

Employees & EPFO

Ang Lifesciences India Limited has a workforce of 459 employees on its EPFO records as of Feb 17, 2025, across 1 active EPFO establishment.

Employee count
459
Active EPFO establishments
1
Employee growth
-19.19%

GST

Ang Lifesciences India has 4 GST registrations: 3 active and 1 cancelled or inactive.

Total GSTINs
4
Active
3
Cancelled / inactive
1
GSTINStateStatusRegistered on
03AAHCA5390H1ZSPunjabActive01 Jul 2017
02AAHCA5390H2ZTHimachal PradeshActive01 Jul 2017
27AAHCA5390H1ZIMaharashtraActive27 Dec 2018

To see the full GST registrations and return filing status of Ang Lifesciences India Limited, buy the company report.

Recent activity

Ang Lifesciences India Limited has 26 board changes on record since 2006: 16 appointments and 10 cessations. The latest: Renu Kaur ceased to be Company Secretary on 16 Dec 2024.

Filing
Ang Lifesciences India Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Chandigarh.
AGM
Ang Lifesciences India Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Ceased
Renu Kaur ceased to be Company Secretary.
Charges
A charge with Others of Rs. 36.50 Cr registered on 31 Dec 2009 with Charge ID 10199453 was modified on 29 Jun 2024.
Ceased
Pawanjit Singh ceased to be Director.
Appointed
Harvinder Singh Dhami was appointed as Director.
Charges
A charge with Others amounted to Rs. 5.00 Cr with Charge ID 100889924 was registered on 05 Mar 2024.
Ceased
Neeraj Gupta ceased to be CFO.
Appointed
Rohit Mittal was appointed as Director.
Ceased
Sudesh Kumari ceased to be Director.
Appointed
Neeraj Gupta was appointed as CFO.
Ceased
Subodh Sharma ceased to be CFO.

54 earlier events are in the company report.

News

Frequently asked questions

Ang Lifesciences India is an active public limited company based in Amritsar, Punjab, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 14 June 2006 (20+ years old) and is registered under CIN L24230PB2006PLC030341. Listed on BSE: 540694.

Ang Lifesciences India reported revenue of ₹92.89 Cr for FY 2025-26 (up 0% YoY) based on consolidated financials.

Ang Lifesciences India has 6 current directors:

The latest financial statements of Ang Lifesciences India on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Ang Lifesciences India is 03AAHCA5390H1ZS, registered in Punjab. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 02AAHCA5390H2ZT (Himachal Pradesh), 27AAHCA5390H1ZI (Maharashtra).

The CIN (Corporate Identification Number) of Ang Lifesciences India is L24230PB2006PLC030341. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Ang Lifesciences India is a listed company as per MCA records. Its shares are listed on BSE (code: 540694).

Ang Lifesciences India has 122 court cases on record: 31 filed by the company and 91 filed against it. 57 are pending. Most are in the district courts.

Ang Lifesciences India was incorporated on 14 June 2006, making it 20+ years old. It is registered with the Registrar of Companies, Chandigarh.

Ang Lifesciences India has 34 deals on record (33 market trades, 1 ipo); the latest was in January 2024.

The peers of Ang Lifesciences India by revenue are XL Laboratories Private Limited, Yeluri Formulations Private Limited, MCW Healthcare Private Limited, Surmount Laboratories Limited, Bio-Med Private Limited and 3 more, all in the Pharma industry (Formulations, Lifesciences), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).